Compare BODI & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BODI | VRCA |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | United States | United States |
| Employees | 270 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.4M | 89.7M |
| IPO Year | N/A | 2018 |
| Metric | BODI | VRCA |
|---|---|---|
| Price | $10.94 | $5.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $15.00 | ★ $17.00 |
| AVG Volume (30 Days) | 18.2K | ★ 25.2K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,577,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.48 | $94.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $4.05 | $3.28 |
| 52 Week High | $16.87 | $9.82 |
| Indicator | BODI | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 56.51 | 48.22 |
| Support Level | $9.47 | $5.32 |
| Resistance Level | $11.18 | $6.29 |
| Average True Range (ATR) | 0.59 | 0.39 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 80.47 | 60.92 |
The Beachbody Co Inc is a fitness and nutrition company providing fitness, nutrition, and stress-reducing programs to its customers. a results-oriented company at the intersection of wellness, technology, and media. The company developed one of the original fitness digital streaming platforms with an extensive library of content containing streaming programs and streaming videos. Company products include Digital Subscriptions, Nutritional Products, and Connected Fitness Products, where the majority of revenue is from Digital Subscriptions. The Company has one operating and reporting segment. Geographically operates in the USA and the rest of the world, with maximum revenue from the United States.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.